[
    {
        "title": "Beckman Coulter, Siemens Healthineers, Abbott, Others Gain 510(k) Clearances in March",
        "summary": "<p><span><span><span>The US Food and Drug Administration granted clearances for testing instruments, a blood clot drug companion diagnostic test, and infectious disease tests, among other devices.</span></span></span></p>",
        "link": "https://www.360dx.com/regulatory-news-fda-approvals/beckman-coulter-siemens-healthineers-abbott-others-gain-510k",
        "published": "Wed, 16 Apr 2025 14:35:26 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda",
        "summary": "<p><span><span><span>The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/agilent-gains-ivdr-certification-expanded-use-cdx-assay-keytruda",
        "published": "Thu, 17 Apr 2025 10:04:09 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage",
        "summary": "<p><span><span><span>The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab). </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/entrogen-colorectal-cancer-ras-mutation-detection-test-nabs-cms-coverage",
        "published": "Mon, 28 Apr 2025 14:27:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "EntroGen Colorectal Cancer RAS Mutation Detection Test Nabs CMS Coverage",
        "summary": "<p><span><span><span>The real-time PCR-based companion diagnostic test identifies patients eligible for treatment with Amgen's Vectibix (panitumumab). </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/entrogen-colorectal-cancer-ras-mutation-detection-test-nabs-cms-coverage",
        "published": "Mon, 28 Apr 2025 14:27:37 EDT",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/roche-receives-fda-breakthrough-label-ai-powered-lung-cancer-companion-diagnostic-test\" hreflang=\"en\">Roche receives FDA breakthrough label for AI-powered lung cancer companion diagnostic test</a>",
        "summary": "Roche\u2019s companion diagnostic aims to identify non-small cell lung cancer patients who may benefit from Datroway, an antibody-drug conjugate developed by AstraZeneca and Daiichi Sankyo.",
        "link": "https://www.fiercebiotech.com/medtech/roche-receives-fda-breakthrough-label-ai-powered-lung-cancer-companion-diagnostic-test",
        "published": "Apr 29, 2025 12:05pm",
        "keywords": [
            "companion diagnostic"
        ]
    },
    {
        "title": "FDA Approves Roche Lung Cancer CDx Assay for Use with AbbVie's Emrelis",
        "summary": "<p><span><span><span>The test detects the MET protein that is over-expressed in some patients with non-squamous non-small cell lung cancer. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/fda-approves-roche-lung-cancer-cdx-assay-use-abbvies-emrelis",
        "published": "Wed, 14 May 2025 17:26:50 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Tempus AI, Verastem Partner to Develop CDx Assay for Ovarian Cancer Combination Treatment",
        "summary": "<p><span><span><span>Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase III RAMP-301 clinical trial. </span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/tempus-ai-verastem-partner-develop-cdx-assay-ovarian-cancer-combination-treatment",
        "published": "Tue, 20 May 2025 09:31:24 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Tempus AI, Verastem Partner to Develop CDx Assay for Ovarian Cancer Combination Treatment",
        "summary": "<p><span><span><span>Tempus' FDA-approved xT CDx test is being used as an investigational assay in Verastem's global Phase III RAMP-301 clinical trial. </span></span></span></p>",
        "link": "https://www.360dx.com/cancer/tempus-ai-verastem-partner-develop-cdx-assay-ovarian-cancer-combination-treatment",
        "published": "Tue, 20 May 2025 09:31:24 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "ODAC votes for Darzalex in smoldering multiple myeloma",
        "summary": "<div class=\"title-top\">MAY 23, 2025 | 2:42 PM PDT | BIOCENTURY | DATA BYTE</div><div class=\"title-bottom\">ODAC VOTES FOR DARZALEX IN SMOLDERING MULTIPLE MYELOMA</div><div class=\"byline\">BY </div>Three other products get negative committee outcomes<a href=\"https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma\">https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma</a><a href=\"https://www.biocentury.com/copyright\">\u00a9 2025 BioCentury Inc. All Rights Reserved</a>",
        "link": "https://www.biocentury.com/article/656014/odac-votes-for-darzalex-in-smoldering-multiple-myeloma",
        "published": "Fri, 23 May 2025 14:42:56 -0700",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "Illumina to Offer Pillar Biosciences CDx Assay In Expanded Partnership",
        "summary": "<p><span><span><span>This summer, Illumina will begin offering its customers the <em>in vitro</em> diagnostic kit, which detects variants in 22 genes.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/illumina-offer-pillar-biosciences-cdx-assay-expanded-partnership",
        "published": "Wed, 28 May 2025 10:20:41 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Illumina to Offer Pillar Biosciences CDx Assay In Expanded Partnership",
        "summary": "<p><span><span><span>This summer, Illumina will begin offering its customers the <em>in vitro</em> diagnostic kit, which detects variants in 22 genes.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/illumina-offer-pillar-biosciences-cdx-assay-expanded-partnership",
        "published": "Wed, 28 May 2025 10:20:41 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Gains IVDR Class C Certification for Lung Cancer CDx",
        "summary": "<p><span><span><span>The molecular diagnostics firm's Idylla EGFR Mutation Test is used to guide targeted therapies for patients with non-small cell lung cancer.</span></span></span></p>",
        "link": "https://www.genomeweb.com/cancer/biocartis-gains-ivdr-class-c-certification-lung-cancer-cdx",
        "published": "Mon, 02 Jun 2025 09:55:11 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Biocartis Gains IVDR Class C Certification for Lung Cancer CDx",
        "summary": "<p><span><span><span>The molecular diagnostics firm's Idylla EGFR Mutation Test is used to guide targeted therapies for patients with non-small cell lung cancer.</span></span></span></p>",
        "link": "https://www.360dx.com/cancer/biocartis-gains-ivdr-class-c-certification-lung-cancer-cdx",
        "published": "Mon, 02 Jun 2025 09:55:11 EDT",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/medtech/asco-guardant-blood-test-guides-breast-cancer-therapy-switches-extending-survival-az-backed\" hreflang=\"en\">ASCO: Guardant blood test guides breast cancer therapy switches, extending survival in AZ-backed study</a>",
        "summary": "A new study sponsored by AstraZeneca suggests that using the Guardant360 CDx test to spot early signs of therapy resistance in advanced breast cancer patients and inform a treatment change could slash the risk of disease progression or death by half.",
        "link": "https://www.fiercebiotech.com/medtech/asco-guardant-blood-test-guides-breast-cancer-therapy-switches-extending-survival-az-backed",
        "published": "Jun 2, 2025 4:21pm",
        "keywords": [
            "CDx"
        ]
    },
    {
        "title": "Research shows new treatment could delay cancer progression in patients with high-risk smoldering multiple myeloma",
        "summary": "A new treatment is showing promise for people with high-risk smoldering multiple myeloma (SMM). This precancerous condition can progress to active multiple myeloma, a type of blood cancer. High-risk SMM carries a higher likelihood of progression.",
        "link": "https://www.sciencedaily.com/releases/2024/12/241210163409.htm",
        "published": "Tue, 10 Dec 2024 16:34:09 EST",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "Obesity linked to detection of blood cancer precursor",
        "summary": "Individuals with obesity are more likely to have monoclonal gammopathy of undetermined significance (MGUS), a benign blood condition that often precedes multiple myeloma, according to new research.",
        "link": "https://www.sciencedaily.com/releases/2024/01/240114202019.htm",
        "published": "Sun, 14 Jan 2024 20:20:19 EST",
        "keywords": [
            "MGUS"
        ]
    },
    {
        "title": "Lenalidomide may delay onset of myeloma-related bone, organ damage",
        "summary": "The largest randomized trial in asymptomatic patients with smoldering multiple myeloma suggests that lenalidomide, a cancer drug, may delay the onset of bone and other myeloma-related organ damage.",
        "link": "https://www.sciencedaily.com/releases/2019/10/191028104212.htm",
        "published": "Mon, 28 Oct 2019 10:42:12 EDT",
        "keywords": [
            "smoldering multiple myeloma"
        ]
    },
    {
        "title": "Blood cancer precursor found in 9/11 firefighters",
        "summary": "A new study reports that New York City firefighters exposed to the 9/11 World Trade Center disaster site face an increased risk for developing myeloma precursor disease (MGUS), which can lead to the blood cancer multiple myeloma.",
        "link": "https://www.sciencedaily.com/releases/2018/04/180426141507.htm",
        "published": "Thu, 26 Apr 2018 14:15:07 EDT",
        "keywords": [
            "MGUS"
        ]
    },
    {
        "title": "<a href=\"https://www.fiercebiotech.com/biotech/cullinan-pens-700m-pact-bcma-bispecific-pair-another-autoimmune-t-cell-engager\" hreflang=\"en\">Cullinan pens $700M pact for BCMA bispecific to pair with another autoimmune T-cell engager</a>",
        "summary": "Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T-cell engager that the biotech plans to pair with its existing CD19 candidate.",
        "link": "https://www.fiercebiotech.com/biotech/cullinan-pens-700m-pact-bcma-bispecific-pair-another-autoimmune-t-cell-engager",
        "published": "Jun 5, 2025 4:40am",
        "keywords": [
            "BCMA"
        ]
    },
    {
        "title": "Randox Laboratories Gains FDA De Novo Clearance for Hemophilia CDx",
        "summary": "<p><span><span><span>The Randox ConcizuTrace ELISA is used to determine the concentration in blood of Novo Nordisk's Alhemo (concizumab-mtci) to aid dose adjustments.</span></span></span></p>",
        "link": "https://www.360dx.com/immunoassays/randox-laboratories-gains-fda-de-novo-clearance-hemophilia-cdx",
        "published": "Thu, 05 Jun 2025 09:41:07 EDT",
        "keywords": [
            "CDx"
        ]
    }
]